| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563142 | VIIV HLTHCARE | Diaromatic substituted compounds as anti-HIV-1 agents |
Oct, 2013
(10 years ago) | |
| US6177101 | VIIV HLTHCARE | Delavirdine high strength tablet formulation |
Jun, 2019
(4 years ago) | |
Rescriptor is owned by Viiv Hlthcare.
Rescriptor contains Delavirdine Mesylate.
Rescriptor has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Rescriptor are:
- US5563142
- US6177101
Rescriptor was authorised for market use on 04 April, 1997.
Rescriptor is available in tablet;oral dosage forms.
The generics of Rescriptor are possible to be released after 07 June, 2019.
Drugs and Companies using DELAVIRDINE MESYLATE ingredient
Market Authorisation Date: 04 April, 1997
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
RESCRIPTOR family patents
